PT  - JOURNAL ARTICLE
AU  - Louis, Renaud
AU  - Pilette, Charles
AU  - Michel, Olivier
AU  - Michils, Alain
AU  - Brusselle, Guy
AU  - Dupont, Lieven
AU  - Poskin, Antoine
AU  - Van Schoor, Jan
AU  - Vancayzeele, Stefaan
AU  - Gurdain, Sandra
TI  - Variability of total serum IgE in moderate-to-severe asthmatic patients
AID  - 10.1183/13993003.congress-2016.PA4171
DP  - 2016 Sep 01
TA  - European Respiratory Journal
PG  - PA4171
VI  - 48
IP  - suppl 60
4099  - http://erj.ersjournals.com/content/48/suppl_60/PA4171.short
4100  - http://erj.ersjournals.com/content/48/suppl_60/PA4171.full
SO  - Eur Respir J2016 Sep 01; 48
AB  - Long-term variability of serum total IgE (sIgEtot) has been reported in asthmatics. This study evaluates the dynamics and the factors predictive of this variability.sIgEtot levels were prospectively measured over 1 year in 41 moderate-to-severe asthmatics treated with high-dose of inhaled corticosteroids and long-acting β2 agonists (and untreated with omalizumab). Patients were divided into 3 groups according to their baseline sIgEtot level: low (≤75 IU/mL; n=10), intermediate (76-700 IU/mL; n=20) or high (>700 IU/mL; n=11). The sIgEtot variability and factors predictive of IgEtot variability were studied.The mean sIgEtot (whole group) fluctuated over 1 year and showed an overall non-significant decrease from baseline (p=0.21). Four to 29% of the sIgEtot variability depended on within-patient variability. No factor predictive of the within-patient variability was identified in the intermediate sIgEtot group. In the low sIgEtot group, however, the level of sIgEtot increased over 1 year in patients exposed to allergens (p<0.001) or who used oral corticosteroids (OCS) (p=0.011), and the odds of having an exacerbation since the previous visit increased by 30% if sIgEtot increased by 100 IU/mL (p<0.0001). Unexpectedly, in the high sIgEtot group, the odds of having an exacerbation since the previous visit decreased by 5% if sIgEtot increased by 100 IU/mL (p=0.005). These trends should be confirmed in a bigger cohort.In this small cohort of moderate-to-severe asthmatics, a limited within-patient variability of sIgEtot levels was observed over 1 year. This variability depended on allergen exposure, OCS use (probably related to exacerbation management) and exacerbations in patients with low and high baseline sIgEtot.